Good afternoon, ladies and gentlemen, and welcome to Lucira Health's Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to Louisa Smith from the Gilmartin Group. Please go ahead. Thank you, Olivia, and good afternoon, everyone. Earlier today, Lucira Health released financial results for the second quarter ending June 30, 2022. A copy of the press release is available on the company's website. Joining me on today's call are Erik Engelson, President and Chief Executive Officer, and Dan George, Chief Financial Officer. Before we begin, I'd like to remind you that during this conference call, the company will make forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the Risk Factors section in the company's most recently filed annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development and manufacturing, product potential, the regulatory environment, sales and marketing strategies, capital resources, or operating performance. With that, I'll now turn the call over to Erik. Thank you, Louisa. Good afternoon, everyone, and thank you for joining us. Welcome to the second quarter 2022 earnings conference call. Lucira had a solid second quarter in which sales continued to be driven by demand for our accurate and easy-to-use molecular COVID-19 test. Second quarter revenues were approximately $26.1 million, a 110% increase over sales in the same period last year. Second quarter 2022 ending cash and cash equivalents was $75 million and inventory was bolstered in advance of anticipated shipments in the fall and winter timeframe. The anticipated dip from Q1 revenue performance is consistent with our previously stated expectations that the calendar year will be bookended based on the prevalence of influenza-like illness infections in the Northern Hemisphere during fall and winter months. Despite the seasonality that we experienced this quarter, we are pleased with our financial performance, delivered in a quarter known to be a light performer for respiratory disease testing in general. Throughout the second quarter, we exercised our manufacturing flexibility, made global regulatory strides, grew our online selling and targeting capabilities, and progressed the product portfolio. As it relates to our existing COVID-19 product, we received approvals from the FDA and Health Canada to extend shelf life to 18 months. As a result, we believe we are well-positioned to respond to anticipated COVID-19 test demand during the upcoming winter respiratory season in the Northern Hemisphere with on-hand inventory. In addition, we submitted a De Novo 510(k) application to the FDA for clearance of our COVID-19 product, anticipating a future day when the EUA may be rescinded. In early July, we announced that the COVID-19 test received a full exemption in New Zealand for immediate commercial use. As is the case in most countries where we have received approval, New Zealand performed its own clinical evaluation prior to granting the full exemption. I'm pleased to share that Lucira's products have consistently performed very well during these independent evaluations. We are readying the COVID and flu product launch in key global markets upon additional regulatory approvals. As previously announced, the EUA for this product has been submitted to the FDA. The early spike in influenza-like illness prevalence reported from Australia during their recent winter sensitized us to the demand that we may see in the Northern Hemisphere this fall and winter. In response, we plan to focus our flexible manufacturing capacity mostly on the COVID and flu test. We are delighted with last week's announcement of the commercial rollout of the COVID and flu product in Canada. Lucira received regulatory approval from Health Canada for the sale of the COVID and flu test with a self-test at home indication. In preparation for this announcement, we built an initial launch quantity of the combo tests, and we plan to ship product in Canada starting this month. The approval in Canada enables patients and healthcare providers to accurately diagnose flu- A, flu- B, and COVID-19 on the spot in 30 minutes or less with lab-quality results. Lucira's digital result capture, transmission, and integration software has been upgraded so that it now works with the combo product. The ability to have an accurate and immediate differential diagnosis for these diseases enables near real-time prescription initiation and treatment. This is accomplished without exposing healthcare professionals to potential infection as a result of at-home testing. We believe that we have sufficient capacity to support anticipated demand, including the manufacture of the COVID and flu product. As I alluded to previously regarding the upcoming Canadian Launch, the speed with which Lucira was able to create the COVID and flu product speaks to the flexibility of the core Lucira technology, as well as to the skill and agility of our team. Because Lucira has been refining the core technology and developing assays for nearly 10 years, we benefited from past work. Going forward, we anticipate leveraging work already accomplished on other assays such as chlamydia and gonorrhea, for example. Longer term, we believe that the flexibility of Lucira's technology, compared with our commercial performance over the last several quarters, demonstrates that strong financial performance can be achieved with modest volumes. In addition, substantial progress was made in the evolution of Lucira Connect, our digital reporting and integration platform. For example, operational speed and several other convenience features were recently improved. We have exciting initiatives in the works that will help close the loop between test results and treatment. For example, upon receiving a positive test result, Lucira Connect will link a patient to high-quality, low-cost providers at the patient's convenience. This, in turn, will result in rapid consultation, prescription, and drug delivery as appropriate. Not only will this provide ease and convenience to patients at home, but it will be a value-added Lucira service to our telehealth partners. We are investing in Lucira Connect both to improve the patient experience and also because it will be good for business. This is only the beginning. We have big plans in development to expand the functionality of Lucira Connect in the near term and look forward to sharing more about this in coming quarters. We believe that technology applied to the needs of our customers is at the core of our mission, and that long-term growth with a digital emphasis opens the door to diverse partnership capabilities and telehealth applications. Lucira views COVID-19 testing as a proxy for the company's capabilities in the emerging category of highly convenient testing. Additionally, we consider ourselves as both a molecular test manufacturer as well as a digital healthcare company. Bain & Company recently announced data on the transition in the way that primary care is delivered. They reported that during the pandemic, 18% of primary care visits were virtual, increasing from 1% in 2018. The share of virtual primary care settled at around 12% at the end of 2021, much higher than pre-pandemic levels. Virtual health could climb to 20% of market penetration by 2030. We believe that Lucira will play an increasingly important role in this paradigm shift in the control of infection and early treatment of respiratory diseases, STIs, and in women's health. Accurate instrument-free molecular tests paired with our flexible digital platform that integrates into partner systems enables convenience and ease of use. We believe that when we look at Lucira, we are seeing stepping stones along a path into the future. More new products, expansion of the digital platform, greater market awareness of Lucira's offerings, greater DTC penetration, international expansion, and decreased cost of goods are our growth drivers. Appropriate stewardship of capital is always front of mind. We are doing very exciting things at Lucira, and we have just gotten started. As always, we recognize and thank the employees, partners, and contractors who execute Lucira's mission with their hard work and enthusiasm. What you have just heard about does not come easily, despite our team's ability to make it appear so. I will now turn the call over to Dan George, our CFO, for a detailed discussion of financials. Thanks, Erik. Please refer to our press release issued earlier today for a summary of our financial results for the second quarter of 2022 and a discussion on and reconciliation of our non-GAAP financial measures. Net sales for the second quarter of 2022 were $26.1 million, up 110% from the second quarter of 2021. Our net revenue was primarily driven by sales directly to consumers, businesses and distributors, healthcare providers, and international customers. Gross profit and gross margin for the second quarter of 2022 were $8 million and 31% respectively, compared to a gross loss and negative gross margin for the second quarter of 2021 of approximately $100,000 and 1% respectively. Our increase in gross profit and gross margin was driven primarily by increased sales and operational efficiencies gained through increased manufacturing output and scale. R&D expenses were $10.8 million in the second quarter of 2022, compared to $10.1 million in the same period in 2021. New product development, clinical activities, and validation and manufacturing activities were primarily drove the increase. Selling, general and administration expenses were $18.6 million in the second quarter of 2022 compared to approximately $6.1 million in the same period in 2021. The increase was primarily related to increasing personnel-related costs and third-party services to facilitate commercial activities and public company compliance. GAAP net loss was $21.7 million in the second quarter of 2022 compared to $16.2 million in the same period in 2021. Non-GAAP net loss was approximately $18.1 million in the second quarter of 2022 compared to $14.7 million in the same period in 2021. The increase in net loss was primarily results of our increased operating expenses. We ended the quarter with $75 million in cash and cash equivalents compared to cash and cash equivalents of $106 million at the end of 2021. The decrease in cash was primarily related to investments made in inventory, partially offset by the closing of the first tranche of our debt financing agreement of $30 million. As a reminder, most of our investments in our contracted manufacturing facility in the Dominican Republic have been completed, allowing us now to manufacture at scale. These investments include automation of certain critical manufacturing steps. We are also investing in our leased facility in San Diego County, which will house commercial operations and other functions. We believe we have the cash necessary to fund our long-term business strategy. I'll turn the call back over to Olivia for Q&A. Thank you. Ladies and gentlemen, if you'd like to ask a question at this time, you will need to press the star one one on your touchtone phone. Again, that's star one one. Please stand by while we compile the Q&A roster. Our first question coming from the line of Brian Weinstein from William Blair. Your line is open. Hey, guys. Good afternoon. This is Griffin in for Brian. Thanks for the questions. Maybe just to start, Dan, on outlook, you know, appreciating that you're not giving any formal guidance here, but maybe can you just talk about how you're thinking about the second half, you know, about halfway through the third quarter here, and we've got the respiratory season coming in the fourth quarter. Just any color on the second half would be helpful. Sure. I mean, to your point, Griffin, we're not giving guidance, but I think you can look at our third quarter as sequential growth, top line sequential growth over Q2. As Erik mentioned in the prepared remarks, we're looking for a strong Q4 and Q1 that coincides with the fall and winter months. Okay. Yeah, appreciate that. Then on the Health Canada over-the-counter, you know, combo approval last week, and you know, you guys already have a CE Mark there. Just first, any color on where ASPs or the combo tests are coming in internationally? Then second, just bigger picture on these markets. Are these, you know, more nice markets to have, or do you think they're real drivers in terms of revenue going forward? Hi, Griffin, Erik here. The ASPs in Canada are similar to the ASPs in the US just converted into Canadian currency. About CAD 98 for the combo and CAD 84 for the COVID test. We see, you know, Canada as an important part of our business going forward. We're very pleased to have this approval. In fact, you know, Health Canada approval marks the first time an at-home self-test for COVID and flu has been approved by a major regulatory body. This was partially pulled by Canada and partially facilitated by Lucira. We're very pleased with this and have expectations that this will be important to Lucira. Okay. On the pipeline, you know, just specifically giving CT/GC, you know, leveraging past work there as an example. Maybe could you just give us an update on, you know, maybe not formal timelines, but where you are in that process? I think last quarter you were undergoing some feasibility evaluation. Just any update on the pipeline beyond respiratory would be helpful. Yeah, absolutely. Just as the COVID and flu product is here today in Canada and hopefully will be soon in the U.S. and elsewhere. The next thing to focus on is our digital offering. It's going to be, we believe, very important to our business because it's gonna enable a connection between a positive test result and prescription and treatment. Making that seamless and easy to use in a digital world without the need for any other instrumentation, readers, et cetera, will make it extremely convenient to users. I would focus on that as the next step in the pipeline, and we're very excited about that. We have been continuing to work on chlamydia, gonorrhea, and other tests in the background, and we'll have more color to share on those in the coming quarters. I don't wanna get too far ahead of ourselves here for resources into the digital effort. I would focus on that as the next delivery. All right. Maybe just to wrap up a bigger picture question, would love to just get some updated thoughts on, you know, maybe the sort of future of diagnostics and the testing in the home, some lessons that you've learned over the past couple of years that are informing some of these thoughts, and why you think Lucira is well-positioned going forward. You know, all it took was this little pandemic to help create this transition. I mean that just, you know, not so facetiously. This would have been a slower transition had it not been for the COVID pandemic. Just as I mentioned that Bain & Company research pointed out, this transition is happening now. It's happening in the U.S., and it's happening in other markets. You know, one of our talented team members internally likes to point out that, back in the day, you used to have to go to Blockbuster to rent a video. Now that's hard to even imagine when you can stream at home. It's the exact same kind of transition in diagnostic testing leading to treatment. Particularly in the case of infectious disease, you know, you don't want people in circulation. You want to be able to treat, test and treat as early as possible. Oftentimes, that means that you're feverish. You don't even have the energy to go out and be tested at that point. I have specific examples of myself and other family members who have kind of suffered through this. I was absolutely positive after returning on an international flight in July that I had flu because it felt everything like flu. It wasn't flu, it was COVID, and I knew that because I could test immediately on Lucira, and then I was able to get treatment following that. I think that's the future. I think the time is now, and Lucira is right at the right point to be able to contribute to this transition, and to build a, you know, very strong business around us. All right. Thanks for the questions. Thank you. Thank you. Our next question coming from the lineup, Derik de Bruin from Bank of America, your line is open. Hi, team. This is John on for Derik de Bruin. I wanted to ask about the cash. Obviously you guys are building up your inventory, and that contributes a significant burn in the quarter. How should we think about the runway or how much runway do you have with all these products coming online, with all the approvals happening internationally and domestically? Sure. As I mentioned, we do believe that we have significant or enough cash capital to see us through our strategic forecast. We do plan on utilizing in the back half of the year the inventory that we've already invested in to facilitate COVID sales. Yeah. I would just add and just underscore that the extension to 18-month shelf life, you know, is very helpful in that regard in removing risk around that inventory. We're very pleased about that. Also compliments to our team on the ability to develop and execute a new product on minimal operating expense. Really well done internally. Going forward, how are you thinking about COVID-19 versus a combo mix in terms of contributions to sales in the back half as well as beyond? Yeah. So the good news is that our manufacturing is flexible enough and these products lend themselves to this flexibility so that we can move back and forth fairly readily. We'll plan to do so. Now that we have the inventory that we have of COVID product, we will prioritize building of the combo product. That just gives us a lot of flexibility and resiliency to any forecasting errors to be able to supply the market. Look, we're gonna have to see how this rolls out. It's hard to imagine that if you can test for both COVID and flu, that you're not gonna do so because both diseases have similar presenting symptoms, and you just don't know. If you're going to test, why not test with a combo? It's hard to imagine not. There are some circumstances where one would want to just use a COVID test, and so we'll have product available for that. Gotcha. Yeah, that makes sense. In the quarter as well as going forward, if you're able to give us any thoughts on what the split was between the pre-procedural screening and B2B and consumer, I'd be curious to know that. You'll see in our 10-Q, I would say, you know, close to 50% of our quarterly revenue came from direct to consumer. That was followed by our international B2B and then healthcare segments. Got it. Thank you. Thank you. Thank you. Our next question coming from the line of Rahul Rakhit from LifeSci Capital. Your line is open. Hey, guys. I guess just one from me, more of a housekeeping question. In terms of thinking about gross margin, I know you said, you mentioned that you're shifting manufacturing towards the combo test. I guess directionally, can you comment on how you're thinking about gross margin moving forward and what impact, you know, if any, early manufacturing of the combo tests could have? Hi, Rahul. I think you're gonna see a really similar impact on gross margin that we've seen in the past. Our gross margin is dependent upon volume. It impacts from overhead absorption to materials costs to our labor rates with our contract manufacturers. I think, you know, when you think about the business, we're looking at being at gross margins north of 60% at volume. I think Q1 is a pretty good proxy for what our business looks like from both a gross margin perspective to a net margin perspective when we achieve, you know, even modest volumes. Got it. Appreciate that. Actually, one more if I can squeeze it in. Just thinking about the combo test, and you know, I know you kind of already gave us the breakdown of revenues across the different channels. Given that the combo test is, you know, is available in Canada and presumably will be, you know, available in the U.S. for, you know, part, if not the majority of the season, are you expecting to see an increase in B2B contracts with, you know, the entry of, you know, the combo test? Or do you still expect those sales primarily to be driven through the DTC channel? Rahul, it will be distributed among our four main channels, which you've named. Whereas in Canada, heavier healthcare/government and then DTC channels. You know, I think from a modeling point of view, I think you can look across the four channels in the U.S. and then a more focused government healthcare DTC in Canada. Got it. Okay. That makes sense. Appreciate it. Thank you, guys. Thank you. I'm showing no further questions at this time. I would now like to turn the call back over to Mr. Erik Engelson for any closing remarks. Thank you, Olivia. Thank you all for your time this afternoon, for your interest in Lucira Health. We are building on significant achievements and greatly appreciate you, our investors. We are delivering the first and only fully disposable molecular flu- A, flu- B, and COVID-19 multiplex test to market in Canada now and hope to do the same in the U.S. if and when approved. We look forward to leveraging our incredible technology to help drive a change in the future of healthcare, and in so doing, to build value for our shareholders. Thank you, and have a great evening. Ladies and gentlemen, that does end our conference for today. Thank you for your participation. You may now disconnect.